Allergan PLC (ACT, Financial), Kimberly-Clark Corp. (KMB, Financial), GGP Inc. (GGP, Financial) and Ventas Inc. (VTR, Financial) have declined to their three-year lows.
Allergan declined to $25.30
The price of Allergan shares declined to $25.30 on April 13, which is only 4.2% above the three-year low of $24.23.
Allergan is an Irish international pharmaceutical company that produces both branded and generic drugs. The company also performs pharmaceutical research and development. The company’s key products include Actonel, Acuvail, Aczone, Lumigan, Namenda, Ozurdex and Rapaflo.
Allergan has a market cap of $118.85 billion; its shares were traded around $25.30 with a price-sales ratio of 3.47.
On April 3. Allergan, in conjunction with Gedeon Richter PLC, announced positive topline results for RGH MD 53, a Phase 3 study of cariprazine for the treatment of adults with major depressive episodes due to bipolar disorder. Last December, the two companies announced positive topline results for the second pivotal trial of cariprazine. In that trial, both cariprazine 1.5 milligram and 3 milligram results were statistically greater than that of the placebo.
Kimberly-Clark declined to $105.84
The price of Kimberly-Clark shares declined to $105.84 on April 13, which is only 2.6% above the three-year low of $103.04.
Kimberly-Clark is an American multinational personal care corporation that produces mostly paper-based consumer products. Some brand name products of this company include Kleenex facial tissue, Kotex feminine hygiene products, Cottonelle, Scott and Andrex toilet paper and Wypall utility wipes.
Kimberly-Clark has a market cap of $37.05 billion; its shares were traded around $105.84 with a price-earnings ratio of 16.54 and a price-sales ratio of 2.06. The trailing 12-month dividend yield is 3.71%. The forward dividend yield is 3.77%. Kimberly-Clark had an annual average earnings growth of 2.40% over the past 10 years.
On April 12, the company announced it has approved a capacity expansion project at its Mobile, Alabama manufacturing facility that will support K-C Professional’s continued bath tissue category growth in North America. With an estimated investment of more than $100 million, the two-year project is projected to deliver improved capacity, greater manufacturing capability and enhanced product quality.
GGP declined to $19.80
The price of GGP shares declined to $19.80 on April 13, which is only 4.9% above the three-year low of $18.83.
GGP is an American real estate investment trust company that owns and manages shopping malls throughout the United States. The company has interest in 120 regional shopping malls in 40 states, and has been in the shopping center industry for more than 60 years. The entire company’s portfolio totals roughly 125,000,000 square feet of retail space.
GGP has a market cap of $18.97 billion; its shares were traded around $19.80 with a price-earnings ratio of 29.12 and a price-sales ratio of 8.08. The trailing 12-month dividend yield is 4.43%. The forward dividend yield is 4.43%. GGP had an annual average earnings growth of 7.90% over the past five years.
On Feb. 7, GGP reported fourth-quarter 2017 financial results. Net income for the quarter was $202 million, or 21 cents per diluted share, compared to $236 million, or 24 cents per diluted share, in the prior-year period. For full-year 2017, net income was $657 million, or 69 cents per diluted share, compared to $1.29 billion, or $1.36 per diluted share, in the prior year.
Ventas declined to $48.54
The price of Ventas shares declined to $48.54 on April 13, which is only 3.4% above the three-year low of $46.87.
Ventas is an American REIT that primarily acquires, develops, leases and manages health care real estate. The company is part of the S&P 500 and its portfolio consists of more than 1,200 assets in the United States, Canada and the United Kingdom. Most of its assets consist of seniors housing communities, medical office buildings and life and science innovation centers.
Ventas has a market cap of $17.3 billion; its shares were traded around $48.54 with a price-earnings ratio of 12.88 and a price-sales ratio of 5.05. The trailing 12-month dividend yield is 6.44%. The forward dividend yield is 6.54%. Ventas had an annual average earnings growth of 2.90% over the past 10 years.
On March 26, Ventas announced it had named Peter J. Bulgarelli, executive vice president of office and president and CEO of Lillibridge Healthcare Services Inc., to lead its ambulatory medical office building and university-based life science portfolio. His position was effective April 9.
Disclosure: I do not own stock in any of the companies mentioned in the article.
